Allogene Therapeutics, Inc. Operating Lease, Payments
Allogene Therapeutics, Inc. (ALLO) reported Operating Lease, Payments of $12.90 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-03-12
- Allogene Therapeutics, Inc. operating lease, payments for the quarter ending 2024-12-31 was $3.20M, a 6.67% increase year-over-year.
- Allogene Therapeutics, Inc. operating lease, payments for the quarter ending 2024-09-30 was $3.10M, a 3.33% increase year-over-year.
- Allogene Therapeutics, Inc. operating lease, payments for the quarter ending 2024-06-30 was $3.10M, a 3.33% increase year-over-year.
- Allogene Therapeutics, Inc. operating lease, payments for the quarter ending 2024-03-31 was $3.10M, a 3.33% increase year-over-year.
- Allogene Therapeutics, Inc. operating lease, payments for fiscal 2025 was $12.90M, a 3.20% increase from fiscal 2024.
- Allogene Therapeutics, Inc. operating lease, payments for fiscal 2024 was $12.50M, a 4.17% increase from fiscal 2023.
- Allogene Therapeutics, Inc. operating lease, payments for fiscal 2023 was $12.00M, a 26.32% increase from fiscal 2022.
- Allogene Therapeutics, Inc. operating lease, payments for fiscal 2022 was $9.50M, a 58.33% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $12.90M 10-K · filed 2026-03-12 | |||
| 2024-12-31 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $6.30M derived: sum of 2 quarters · filed 2025-03-13 | $9.40M derived: sum of 3 quarters · filed 2025-03-13 | $12.50M 10-K · filed 2025-03-13 |
| 2024-09-30 | $3.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $6.20M derived: sum of 2 quarters · filed 2024-11-07 | $9.30M 10-Q · filed 2024-11-07 | $12.30M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | $3.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $6.20M 10-Q · filed 2024-08-07 | $9.20M derived: sum of 3 quarters · filed 2024-08-07 | $12.20M derived: sum of 4 quarters · filed 2024-08-07 |
| 2024-03-31 | $3.10M 10-Q · filed 2024-05-13 | $6.10M derived: sum of 2 quarters · filed 2024-05-13 | $9.10M derived: sum of 3 quarters · filed 2024-05-13 | $12.10M derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $6.00M derived: sum of 2 quarters · filed 2024-03-14 | $9.00M derived: sum of 3 quarters · filed 2024-03-14 | $12.00M 10-K · filed 2024-03-14 |
| 2023-09-30 | $3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $6.00M derived: sum of 2 quarters · filed 2023-11-02 | $9.00M 10-Q · filed 2023-11-02 | $15.90M derived: sum of 4 quarters · filed 2024-03-14 |
| 2023-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $6.00M 10-Q · filed 2023-08-02 | $12.90M derived: sum of 3 quarters · filed 2024-03-14 | $13.50M derived: sum of 4 quarters · filed 2024-03-14 |
| 2023-03-31 | $3.00M 10-Q · filed 2023-05-03 | $9.90M derived: sum of 2 quarters · filed 2024-03-14 | $10.50M derived: sum of 3 quarters · filed 2024-03-14 | $10.50M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-12-31 | $6.90M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $7.50M derived: sum of 2 quarters · filed 2024-03-14 | $7.50M derived: sum of 3 quarters · filed 2024-03-14 | $9.50M 10-K/A · filed 2024-03-14 |
| 2022-09-30 | $600.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $600.00K derived: sum of 2 quarters · filed 2022-11-02 | $2.60M 10-Q · filed 2022-11-02 | $4.50M derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $2.00M 10-Q · filed 2022-08-09 | $3.90M derived: sum of 3 quarters · filed 2022-08-09 | $5.60M derived: sum of 4 quarters · filed 2022-08-09 |
| 2022-03-31 | $2.00M 10-Q · filed 2022-05-04 | $3.90M derived: sum of 2 quarters · filed 2022-05-04 | $5.60M derived: sum of 3 quarters · filed 2022-05-04 | $7.00M derived: sum of 4 quarters · filed 2022-05-04 |
| 2021-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $3.60M derived: sum of 2 quarters · filed 2022-02-23 | $5.00M derived: sum of 3 quarters · filed 2022-02-23 | $6.00M 10-K · filed 2022-02-23 |
| 2021-09-30 | $1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $3.10M derived: sum of 2 quarters · filed 2021-11-04 | $4.10M 10-Q · filed 2021-11-04 | $6.10M derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-06-30 | $1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $2.40M 10-Q · filed 2021-08-04 | $4.40M derived: sum of 3 quarters · filed 2021-08-04 | $5.80M derived: sum of 4 quarters · filed 2021-08-04 |
| 2021-03-31 | $1.00M 10-Q · filed 2021-05-05 | $3.00M derived: sum of 2 quarters · filed 2021-05-05 | $4.40M derived: sum of 3 quarters · filed 2021-05-05 | $5.80M derived: sum of 4 quarters · filed 2021-05-05 |
| 2020-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $3.40M derived: sum of 2 quarters · filed 2021-02-25 | $4.80M derived: sum of 3 quarters · filed 2021-02-25 | $6.20M 10-K · filed 2021-02-25 |
| 2020-09-30 | $1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $2.80M derived: sum of 2 quarters · filed 2020-11-04 | $4.20M 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $2.80M 10-Q · filed 2020-08-05 | ||
| 2020-03-31 | $1.40M 10-Q · filed 2020-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |